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Abstract: Macrophages (Mϕs) are instrumental regulators of the immune response whereby they
acquire diverse functional phenotypes following their exposure to microenvironmental cues that
govern their differentiation from monocytes and their activation. The complexity and diversity of
the mycobacterial cell wall have empowered mycobacteria with potent immunomodulatory capac-
ities. A heat-killed (HK) whole-cell preparation of Mycobacterium obuense (M. obuense) has shown
promise as an adjunctive immunotherapeutic agent for the treatment of cancer. Moreover, HK
M. obuense has been shown to trigger the differentiation of human monocytes into a monocyte-
derived macrophage (MDM) type named Mob-MDM. However, the transcriptomic profile and
functional properties of Mob-MDMs remain undefined during an activation state. Here, we char-
acterized cytokine/chemokine release patterns and transcriptomic profiles of lipopolysaccharide
(LPS)/interferon γ (IFNγ)-activated human MDMs that were differentiated with HK M. obuense
(Mob-MDM(LPS/IFNγ)), macrophage colony-stimulating factor M-MDM(LPS/IFNγ)), or gran-
ulocyte/macrophage colony-stimulating factor (GM-MDM(LPS/IFNγ)). Mob-MDM(LPS/IFNγ)
demonstrated a unique cytokine/chemokine release pattern (interleukin (IL)-10low, IL-12/23p40low,
IL-23p19/p40low, chemokine (C-x-C) motif ligand (CXCL)9low) that was distinct from those of M-
MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ). Furthermore, M-MDM(LPS/IFNγ) maintained IL-10
production at significantly higher levels compared to GM-MDM(LPS/IFNγ) and Mob-MDM(LPS/
IFNγ) despite being activated with M1-Mϕ-activating stimuli. Comparative RNA sequencing
analysis pointed to a distinct transcriptome profile for Mob-MDM(LPS/IFNγ) relative to both M-
MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ) that comprised 417 transcripts. Functional gene-set
enrichment analysis revealed significant overrepresentation of signaling pathways and biological
processes that were uniquely related to Mob-MDM(LPS/IFNγ). Our findings lay a foundation for
the potential integration of HK M. obuense in specific cell-based immunotherapeutic modalities such
as adoptive transfer of Mϕs (Mob-MDM(LPS/IFNγ)) for cancer treatment.
Keywords: Mycobacterium obuense; immunomodulation; monocyte-derived macrophages; macrophage
activation; RNA sequencing
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1. Introduction
Macrophages (Mϕs) are known for their exceptional degree of plasticity whereby
they display diversified phenotypes and functions following exposure to various cues
from the surrounding milieu [1]. Human Mϕs are generally classified into “proinflam-
matory/classically activated” M1 and “anti-inflammatory/alternatively activated” M2
phenotypes. M1-Mϕs produce significant amounts of proinflammatory cytokines (e.g.,
interleukin (IL)-1β, IL-6, IL-12, IL-23, and tumor necrosis factor alpha (TNF-α)) and retain
robust and antitumor capabilities in certain stages of cancer development and progres-
sion. In contrast, M2-Mϕs release substantial amounts of anti-inflammatory cytokines
(e.g., IL-10 and transforming growth factor (TGF-β)) and contribute to tissue regeneration,
angiogenesis, and tumor progression [2,3]. To obtain activated human Mϕ phenotypes
in vitro, isolated monocytes are initially primed with maturation/differentiation factors
such as granulocyte/macrophage colony-stimulating factor (GM-CSF) and macrophage
colony-stimulating factor (M-CSF) to generate nonactivated M1-like and M2-like monocyte-
derived macrophages (MDMs), respectively [4–6]. Following the maturation or differenti-
ation stage, M1-like Mϕs are stimulated with lipopolysaccharide (LPS) and interferon γ
(IFNγ) to induce the activated M1-Mϕ phenotype, while M2-like Mϕs are stimulated with
interleukin (IL)-4 ± IL-13, IL-10, TGF-β, immune complexes, or glucocorticoids to induce
various activated M2-Mϕ phenotypes [7,8].
The complexity and diversity of the mycobacterial cell wall have empowered my-
cobacteria with a potent immunomodulatory capacity [9]. Such mycobacteria-associated
immunomodulatory activities have been mainly attributed to various mycobacterial cell
wall components, serving as pathogen-associated molecular patterns (PAMPs) that are
recognized by specific pathogen recognition receptors (PRRs) expressed on various innate
immune cells, including monocytes, and macrophages [10,11]. Over the past 10 years, there
has been an increasing interest in exploring the immunotherapeutic potential [12–14] and
the in vitro immunomodulatory properties of a heat-killed (HK) whole-cell preparation of
Mycobacterium obuense (M. obuense), also known as IMM-101 [15–18]. In a phase I clinical
trial, HK M. obuense was shown to be safe and well tolerated when used alone in patients
with stage III/IV metastatic melanoma [12]. A phase II clinical trial reported that a combi-
nation treatment of HK M. obuense and conventional gemcitabine chemotherapy was safe
and resulted in a significant increase in the overall survival of patients with metastatic pan-
creatic cancer [13]. HK M. obuense is currently being investigated as an immunotherapeutic
agent in combination with anti-PD-1 in a phase II trial (NCT03711188) involving patients
with advanced melanoma. In addition, an ongoing phase III clinical trial (NCT04442048)
is examining whether immunization with HK M. obuense can diminish the frequency of
severe respiratory and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-
related infections among cancer patients. Our group previously demonstrated the ability
of HK M. obuense to modulate the surface expression of different categories of cells surface
receptors on whole-blood human monocytes [16], as well as to trigger the differentiation of
human monocytes into a nonactivated Mϕ type (Mob-MDM) that is quite distinct from the
nonactivated Mϕ phenotypes generated by M-CSF (M-MDM) or GM-CSF (GM-MDM) [18].
Nonactivated Mob-MDMs exhibited significantly increased and spontaneous release of the
proinflammatory cytokines IL-6 and TNF-α and chemokine (C-x-C) motif ligand (CXCL)
8, relative to nonactivated M-MDMs and GM-MDMs. Moreover, all three nonactivated
Mϕ types did not release spontaneous detectable levels of IL-10, IL-12p40, IL-12p70, and
IL-23p19/p40. In the same study, genome-wide gene expression profiling combined with
functional enrichment analysis revealed unique gene sets and networks suggestive of a
proinflammatory M1-like Mϕ phenotype in Mob-MDMs compared with both M-MDMs
and GM-MDMs [18].
Because human nonactivated MDMs display a distinct pattern of phenotypic and
functional characteristics compared to activated MDMs [19,20], this study sought to
characterize M-MDMs, GM-MDMs, and Mob-MDMs during an activated state. There-
fore, the three above-mentioned nonactivated MDM types were activated with LPS and
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IFNγ to generate the following MDM types: M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ),
and Mob-MDM(LPS/IFNγ), whereby the Mϕ nomenclature proposed by Murray et al.
was adopted [1]. The aims of this study were, first, to characterize the cytokine and
chemokine secretion patterns of M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-
MDM(LPS/IFNγ) and, second, to perform genome-wide transcriptome profiling of the
three LPS/IFNγ-activated MDM types.
2. Results
2.1. Patterns of Cytokine and Chemokine Secretion by M-MDM(LPS/IFNγ),
GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ)
To examine the functional characteristics of different LPS/IFNγ-activated MDMs,
culture supernatants of M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/
IFNγ) were screened for various secreted cytokines and chemokines. GM-MDM(LPS/IFNγ)
displayed significantly (p < 0.05) higher secretion levels of the M1-Mϕ signature cytokine,
IL-12/23p40, as compared to M-MDM(LPS/IFNγ) and Mob-MDM(LPS/IFNγ) (~7.5-fold
and ~10-fold, respectively; Figure 1). Of note, GM-MDM(LPS/IFNγ) were found to release
substantial amounts of another M1-Mϕ marker, IL-23p19/p40, while M-MDM(LPS/IFNγ)
and Mob-MDM(LPS/IFNγ) were characterized by their undetectable and low-level release
of IL-23p19/p40, respectively (Figure 1). Additionally, GM-MDM(LPS/IFNγ) showed
a trend toward higher IL-12p70 production relative to M-MDM(LPS/IFNγ) and Mob-
MDM(LPS/IFNγ); however, this difference did not achieve statistical significance (Figure 1).
Supernatants from M-MDM(LPS/IFNγ) cultures demonstrated significantly (p < 0.05)
increased levels of chemokine (C-C motif) ligand 5 (CCL5) and the M2-Mϕ signature
cytokine marker, IL-10, as well as decreased levels of M1-Mϕ marker, IL-6, when com-
pared with supernatants from GM-MDM(LPS/IFNγ) and Mob-MDM(LPS/IFNγ) cul-
tures (Figure 1). In addition, Mob-MDM(LPS/IFNγ) exhibited significantly (p < 0.05)
reduced CXCL9 secretion as compared to M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ)
(Figure 1). Mob-MDM(LPS/IFNγ) released lower amounts of CCL2 and CCL22 as com-
pared to GM-MDM(LPS/IFNγ). No significant differences were detected between M-
MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ) in terms of TGF-β1,
TNF-α, and M-CSF production (Figure 1). All in all, the above-reported data strongly indi-
cate that Mob-MDM(LPS/IFNγ) are characterized by a distinct cytokine and chemokine
secretion pattern (IL-10low, IL-12/23p40low, IL-23p19/p40low, and CXCL9low) from that of
M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ). Moreover, the cytokine release patterns
of GM-DM(LPS/IFNγ) and M-MDM(LPS/IFNγ) strongly correlate with those of M1-Mϕs
and M2-Mϕs, respectively. The cytokine and chemokine secretion profiles of nonactivated
M-MDMs, GM-MDMs, and Mob-MDMs have been characterized in a previous study [18].




Figure 1. Cytokine and chemokine secretion by lipopolysaccharide (LPS)/interferon γ (IFNγ)-activated monocyte-derived 
macrophages (MDMs). Macrophage colony-stimulating factor MDMs (M-MDMs), granulocyte/macrophage colony-stim-
ulating factor MDMs (GM-MDM), and heat-killed Mycobacterium obuense MDMs (Mob-MDMs) were generated and acti-
vated with LPS and IFNγ for 24 h as described below (see the Materials and Methods section (Section 4)). Cytokine and 
chemokine levels were determined in M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ) culture su-
pernatants by ELISA. Scatter plots demonstrate chemokine or cytokine concentration (pg/mL) in different LPS/IFNγ-acti-
vated MDM culture supernatants. Horizontal bars indicate group mean values of cytokine or chemokine concentration of 
at least 8 independent donors. One-way ANOVA, followed by Tukey’s post-hoc test, was performed to determine statis-
tically significant differences in cytokine/chemokine secreted levels (* p < 0.05). Circles represent M-MDM(LPS/IFNγ), 
squares represent GM-MDM(LPS/IFNγ) and triangles represent Mob-MDM(LPS/IFNγ). 
Figure 1. Cytokine and chemokine secretion by lipopolysaccharide (LPS)/interferon γ (IFNγ)-activated monocyte-derived
macrophages (MDMs). Macrophage colony-stimulating factor MDMs (M-MDMs), granulocyte/macrophage colony-
stimulating factor MDMs (GM-MDM), and heat-killed Mycobacterium obuense MDMs (Mob-MDMs) were generated and
activated with LPS and IFNγ for 24 h as described below (see the Materials and Methods section (Section 4)). Cytokine and
chemokine levels were determined in M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IF γ) culture
supernatants by ELISA. Scatter plots demonstrate chemokine or cytokine concentration (pg/mL) in differe t LPS/IFNγ-
activated MDM culture supernatants. Horizontal bars indicate group mean values of cytokine or chemokine concentration
of at least 8 independent donors. One-way ANOVA, followed by Tukey’s post-hoc test, was performed to determine
statistically significant differences in cytokine/chemokine secreted levels (* p < 0.05). Circles represent M-MDM(LPS/IFNγ),
squares represent GM-MDM(LPS/IFNγ) and triangles represent Mob-MDM(LPS/IFNγ).
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2.2. Comparative Whole-Transcriptome Analysis of M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ),
and Mob-MDM(LPS/IFNγ)
RNA sequencing (RNA-Seq) was carried out to profile the transcriptomes of LPS/IFNγ-
activated Mob-MDMs, M-MDMs, and GM-MDMs, each derived from four independent
donors. Sample preparation, sequencing, and analytical methods for RNA-Seq analysis
of the three LPS/IFNγ-activated MDMs were performed as previously described [18].
Following filtering criteria (≥2-fold change cut-off, p < 0.05), a total of 1546 transcripts
were differentially expressed among M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and
Mob-MDM(LPS/IFNγ) (Supplementary Materials Table S1). Of the 1546 differentially
expressed transcripts, 260 were identified as being upregulated in M-MDM(LPS/IFNγ)
versus GM-MDM(LPS/IFNγ), while 262 were upregulated in GM-MDM(LPS/IFNγ) ver-
sus M-MDM(LPS/IFNγ). Several M1-Mϕ-related genes belonging to different categories
(e.g., IL6, IL12B (encoding for IL-12/23p40), IL23A (encoding for IL-23p19), and IL8 (en-
coding for CXCL8)) were expressed at significantly higher levels in GM-MDM(LPS/IFNγ)
as compared to M-MDM(LPS/IFNγ) (Table 1). On the other hand, the expression lev-
els of a set of M2-Mϕ-associated genes (e.g., ADAMDEC1, CCL17, CD36, CD163, IL10,
MAOA, SEPP1, SOCS2, and STAB1) were significantly higher in M-MDM(LPS/IFNγ)
relative to GM-MDM(LPS/IFNγ) (Table 1). Accordingly, our results clearly indicate that
GM-MDM(LPS/IFNγ) and M-MDM(LPS/IFNγ) display M1-like and M2-like Mϕ proper-
ties, respectively.
Table 1. Select transcripts significantly differentially expressed between lipopolysaccharide (LPS)/interferon γ (IFNγ)-
activated human monocyte-derived macrophages (MDMs) that were differentiated with macrophage colony-stimulating
factor (M-MDM(LPS/IFNγ)) and granulocyte/macrophage colony-stimulating factor (GM-MDM(LPS/IFNγ)).
RefSeq Transcript ID Gene Symbol Entrez Gene Name FC (vs. GM-MDM(LPS/IFNγ))
NM_002933 RNASE1 Ribonuclease, RNase A family, 1 20.65
NM_006274 CCL19 Chemokine (C-C motif) ligand 19 18.02
NM_001400 S1PR1 sphingosine-1-phosphate receptor 1 11.92
NM_000240 MAOA monoamine oxidase A 10.01
NM_000572 IL10 Interleukin 10 7.88
NM_203416 CD163 CD163 molecule 7.44
NM_004244 CD163 CD163 molecule 7.38
NM_015136 STAB1 Stabilin 1 6.72
NM_001270471 SOCS2 Suppressor of cytokine signaling 2 5.16
NM_001270467 SOCS2 Suppressor of cytokine signaling 2 3.97
NM_014479 ADAMDEC1 ADAM-like, decysin 1 3.64
NM_001127443 CD36 CD36 molecule 3.55
NM_002987 CCL17 Chemokine (C-C motif) ligand 17 3.45
NM_003877 SOCS2 Suppressor of cytokine signaling 2 3.22
NM_004994 MMP9 Matrix metallopeptidase 9 2.82
NM_001127444 CD36 CD36 molecule 2.82
NM_001001547 CD36 CD36 molecule 2.63
NM_001001548 CD36 CD36 molecule 2.62
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Table 1. Cont.
RefSeq Transcript ID Gene Symbol Entrez Gene Name FC (vs. GM-MDM(LPS/IFNγ))
NM_181054 HIF1A




NM_000072 CD36 CD36 molecule 2.29
NM_005410 SEPP1 Selenoprotein P, plasma, 1 2.13
NM_016584 IL23A Interleukin 23 subunit alpha (p19) −2.34
NM_000584 IL8 Chemokine (C-X-C motif) ligand 8 −2.46
NM_000759 CSF3 Colony-stimulating factor 3 −2.49
NM_003775 S1PR4 Sphingosine-1-phosphate receptor 4 −2.64
NM_001764 CD1B CD1b molecule −3.39
NM_000575 IL1A Interleukin 1 alpha −3.63
NM_002438.1 MRC1 Mannose receptor, C type 1 (CD206) −3.96
NM_001025194 CES1 Carboxylesterase 1 −3.97
NM_002990 CCL22 Chemokine (C-C motif) ligand 22 −4.08
NM_001025195 CES1 Carboxylesterase 1 −4.22
NM_001207019 FCER2 Fc fragment of IgE receptor II −4.23
NM_002438 MRC1 Mannose receptor, C type 1 (CD206) −4.37
NM_001266 CES1 carboxylesterase 1 −4.38
NM_000600 IL6 Interleukin 6 −4.63
NM_006770 MARCO Macrophage receptor withcollagenous structure −7.49
NM_002981 CCL1 Chemokine (C-C motif) ligand 1 −8.71
NM_002187 IL12B Interleukin 12B (p40) −15.28
FC: fold change.
Hierarchical clustering analysis was performed to characterize gene clusters with
differential patterns of expression among the three LPS/IFNγ-activated MDMs. A two-
dimensional hierarchical clustering of both transcripts and samples demonstrated that
Mob-MDM(LPS/IFNγ) formed a separate cluster from both M-MDM(LPS/IFNγ) and
GM-MDM(LPS/IFNγ) (Figure 2). We noted two gene clusters that displayed the lowest
and highest expression in Mob-MDM(LPS/IFNγ) relative to both M-MDM(LPS/IFNγ)
and GM-MDM(LPS/IFNγ) (Figure 2). These two clusters comprised 417 transcripts that
were differentially expressed in Mob-MDM(LPS/IFNγ) versus both M-MDM(LPS/IFNγ)
and GM-MDM(LPS/IFNγ), but not between the latter two MDM types (Supplementary
Materials Table S2). Gene ontology analysis revealed that Mob-MDM(LPS/IFNγ) pro-
files included cytokines/chemokines (e.g., CSF2, CXCL1, CXCL2, CXCL3, CXCL5, CXCL9,
CXCL10, CXCL11, IL1B, and IL36G), G-protein-coupled receptors (e.g., CXCR4 and CXCR6),
enzymes such as peptidases, phosphatases, and kinases (e.g., PRKCQ and CSNK1G3), trans-
membrane receptors (e.g., IL2RB and SEMA4D), transcription regulators (e.g., ANKRD22
and ASB2), and others such as SIGLEC10 (Supplementary Materials Table S2).
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Figure 2. Whole-transcriptome analysis of lipopolysaccharide (LPS)/interferon γ (IFNγ)-activated monocyte-derived
macrophages (MDMs). Macrophage colony-stimulating factor MD s (M-MDMs), granulocyte/macr phage colony-
stimulating factor MDMs (GM-MDMs), and heat-killed Mycobacterium obuense (Mob-MDMs) were generated
and activated with LPS and IFNγ for 24 h as described below (see the aterials and Methods section (Section 4)) from
four healthy donors (n = 12). Total RNA was isolated and then sequenced using the Ion Torrent platform (as described
in the Materials and Methods section (Section 4)). Sequence alignment, followed by quantification of transcriptomes,
was performed (as described in the Materials and Methods section (Section 4)). Transcripts (n = 1546) differentially
expressed betwee M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ) w re identifi d based on a
fixed-eff cts model with ANOVA and analyzed by hierarchic l clustering. Columns represent samples and rows constitute
the differentially expressed transcripts (yellow, relatively upregulated; blue, relatively downregulated).
Orthogonal validation of RNA-Seq data found similar differential patterns of expres-
sion of select cytokines/chemokines, namely IL8 (encodes for CXCL8), IL10 (encodes for
IL-10), IL12B (encodes for IL-12/23p40), and TNF (encodes for TNF-α), at both the transcript
(Figure 3A) and protein (Figure 3B) levels in M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ),
and Mob-MDM(LPS/IFNγ).
Int. J. Mol. Sci. 2021, 22, 7214 8 of 18
Int. J. Mol. Sci. 2021, 22, x 8 of 18 
 
 
Orthogonal validation of RNA-Seq data found similar differential patterns of expres-
sion of select cytokines/chemokines, namely IL8 ( encodes for CXCL8), IL10 (encodes for 
IL-10), IL12B (encodes for IL-12/23p40), and TNF (encodes for TNF-α), at both the tran-
script (Figure 3A) and protein (Figure 3B) levels in M-MDM(LPS/IFNγ), GM-
MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ). 
 
Figure 3. Confirmation of select cytokines and chemokines identified to be differentially expressed 
among lipopolysaccharide (LPS)/interferon γ (IFNγ)-activated monocyte-derived macrophages 
(MDMs) by RNA sequencing (RNA-Seq). Macrophage colony-stimulating factor MDMs (M-
MDMs), granulocyte/macrophage colony-stimulating factor MDMs (GM-MDMs), and heat-killed 
Mycobacterium obuense MDMs (MobMDMs) were generated and were activated with LPS/IFNγ for 
24 h (as described in the Materials and Methods section (Section 4)). The differential expression of 
(A) select cytokine/chemokine transcripts, namely interleukin 10 (IL10) (encodes IL-10), IL12B (en-
codes IL-12/23p40), tumor necrosis factor (TNF) (encodes TNF-α), and IL8 (encodes chemokine C-
x-C motif ligand 8 (CXCL8)), in LPS/IFNγ-activated MDMs was confirmed at (B) the protein level 
by analysis of their secreted levels in M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-
MDM(LPS/IFNγ) culture supernatants by ELISA. (A) Column bars represent fold change for each 
cytokine or chemokine transcript, and (B) scatter plots demonstrate cytokine or chemokine concen-
tration in culture supernatants of the three LPS/IFNγ-activated MDM types. The same MDMs were 
used for RNA-Seq and ELISA experiments. Horizontal bars indicate group mean values of cytokine 
or chemokine concentration of at least 4 independent donors. One-way ANOVA, followed by 
Tukey’s post-hoc test, was performed to determine statistically significant differences in cyto-
kine/chemokine secreted levels (* p < 0.05). Circles represent M-MDM(LPS/IFNγ), squares represent 
GM-MDM(LPS/IFNγ) and triangles represent Mob-MDM(LPS/IFNγ). 
Figure 3. Confirmation of select cytokines and chemokines identified to be differ ntially expressed
among lipopolysaccharide (LPS)/interferon γ (IFNγ)-activated monocyte-derived macrophages
(MDMs) by RNA sequencing (RNA-Seq). Macrophage colony-stimulating factor MDMs (M-MDMs),
granulocyte/macrophage colony-stimulating factor MDMs (GM-MDMs), and heat-killed Mycobac-
terium obuense MDMs (MobMDMs) were generated and were activated with LPS/IFNγ for 24 h (as
described in the Materials and Methods section (Section 4)). The differential expression of (A) select
cytokine/che okine transcripts, namely interleukin 10 (IL10) (encodes IL-10), IL12B (encodes IL-
12/23p40), tumor necrosis factor (TNF) (encodes TNF-α), a d IL8 (encodes chemoki e C-x-C motif
ligand 8 (CXCL8)), in LPS/IFNγ-activated MDMs was confirmed at (B) the protein level by analysis of
their secreted levels in M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ) cul-
ture supernatants by ELISA. (A) Column bars represent fold change for each cytokine or chemokine
transcript, and (B) scatter plots demonstrate cytokine or chemokine concentration in culture super-
natants of the three LPS/IFNγ-activated MDM types. The same MDMs were used for RNA-Seq
and ELISA experiments. Horizontal bars indicate group mean values of cytokine or chemokine
concentration of at least 4 independent donors. One-way ANOVA, followed by Tukey’s post-hoc
test, was performed to determine statistically significant differences in cytokine/chemokine secreted
levels (* p < 0.05). Circles represent M-MDM(LPS/IFNγ), squares represent GM-MDM(LPS/IFNγ)
and triangles represent Mob-MDM(LPS/IFNγ).
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Canonical pathway enrichment analysis identified several predicted signaling path-
ways that were significantly altered in Mob-MDM(LPS/ IFNγ) relative to both M-MDM(LPS/
IFNγ) and GM-MDM(LPS/IFNγ), but not between the latter two MDM types. These com-
prised, among others, activated NF-κB signaling, TREM1 signaling, and repressed p53
signaling (Table 2).
Table 2. Signaling pathways that are uniquely modulated in lipopolysaccharide (LPS)/interferon γ (IFNγ)-activated human
monocyte-derived macrophages (MDMs) that were differentiated with HK M. obuense (Mob-MDM(LPS/IFNγ)) relative











Endothelin-1 Signaling 2.65 −0.38
NF-κB Signaling 2.65 −0.82
Estrogen-mediated S-phase Entry 2.45 1.63
Mitotic Roles of Polo-Like Kinase 2.45 0.82
Role of IL-17F in Allergic Inflammatory Airway Diseases 2.24 0.45
TREM1 Signaling 2.24 −0.45
p53 Signaling −2.65 1.13
We then performed topological network analysis to predict the activation or inhibition
of potential upstream regulators of the detected set of differentially expressed genes unique
to Mob-MDM(LPS/IFNγ). A total of 186 upstream regulators (121 activated (z-score ≥ 2)
and 65 inhibited (z-score ≤ −2)) were identified in Mob-MDM(LPS/IFNγ) relative to M-
MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ), but not between the latter MDM types (Sup-
plementary Materials Table S3). Those predicted upstream regulators comprised various cy-
tokines/chemokines, chemical drugs, transmembrane receptors, bacterial components, and
others. CSF2 (GM-CSF; z-score = 4.61) and the LY294002 (z-score = −4.31) were predicted
as the top activated and inhibited upstream regulators, respectively (Supplementary Mate-
rials Table S3). In addition, gene-set and network analysis identified biological functions
(n = 100) significantly affected by the uniquely differentially expressed transcripts in Mob-
MDM(LPS/IFNγ) compared to M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ), but not
between the latter two MDM types (Supplementary Materials Table S4). The identified bio-
logical functions predicted to be uniquely activated (z-score ≥ 2) in Mob-MDM(LPS/IFNγ)
included, among others, activation of blood cells/leukocytes, migration/cell movement of
myeloid cells and Mϕs, and synthesis of reactive oxygen species (Supplementary Materi-
als Table S4). Collectively, RNA-Seq analysis revealed a distinct transcriptome profile of
Mob-MDM(LPS/IFNγ) from both M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ).
3. Discussion
Mϕ activation is a multifaceted and dynamic mechanism that can generate various
Mϕ states with a diverse range of functional outcomes [21,22]. However, the preactivation
process whereby monocytes are differentiated into Mϕs plays a dominant role in shap-
ing the final activation state of Mϕs irrespective of the adopted stimulus. Traditionally,
GM-CSF and M-CSF have been widely used to induce monocyte-to-Mϕ differentiation
and to prime Mϕs toward the nonactivated pre-M1 (GM-MDM) and pre-M2 (M-MDM)
Mϕ phenotypes, respectively [23]. Evidence from previous studies has confirmed the
immunomodulatory properties and immunotherapeutic potentials of HK whole-cell my-
cobacteria namely, M. vaccae and M. obuense. More importantly, the safety of both HK
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mycobacteria is proven and well documented in several studies whereby mild adverse
events were noted following the administration of either preparation to cancer [12,13,24]
and human immunodeficiency virus (HIV) [25] patients. Thus, HK whole-cell preparations
of M. vaccae and M. obuense have a major advantage over Bacillus Calmette–Guérin (BCG) in
terms of their favorable safety and tolerability. Despite its successful usage in the treatment
of nonmuscle/noninvasive bladder cancer, BCG might cause in certain cases severe and
life-threatening adverse events such as local or systemic infections with BCG [26]. It has
been well documented from earlier studies that various viable and killed mycobacterial
species can alter the activation state of human Mϕs [27,28]. In this manner, data from our
previous phenotypic, functional, and transcriptomic studies have indicated that HK M.
obuense, an immunomodulator of both the innate and adaptive immune responses, pro-
motes the differentiation of human monocytes into a nonactivated Mϕ type (Mob-MDM)
that acquire proinflammatory properties suggestive of an M1-like Mϕ phenotype [18].
In this study, we aimed to gain deeper insights into the cytokine/chemokine secretion
patterns and transcriptome profiles of Mob-MDMs, M-MDMs, and GM-MDMs following
their LPS/IFNγ-mediated activation.
In the present work and consistent with previous reports, GM-MDM(LPS/IFNγ)
produced significantly higher levels of CCL22 [7,29], IL-6 [29,30], IL-12/23p40 [7,29,31],
and IL-23p19/p40 [19] and significantly lower levels of IL-10 [29–32] as compared to M-
MDM(LPS/IFNγ). On the other hand, a study by Vogel et al. did not find any significant
difference in IL-10 secretion between M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ) [8].
Moreover, in sharp contrast to Verreck et al., who reported the absence of detectable
levels of IL-12/23p40 in M-MDM(LPS/IFNγ) culture supernatants [19], findings from
this study and from previous studies [7,31] have found M-MDM(LPS/IFNγ) to release
detectable amounts of IL-12/23p40, although, to a significantly lower level than that
released by GM-MDM(LPS/IFNγ). Additionally, previous studies have reported that
IL-12p70 [7,32] and TNF-α [30,32] were secreted at significantly higher levels by GM-
MDM(LPS/IFNγ) relative to M-MDM(LPS/IFNγ). This study only showed an over-
all trend, but with no statistical significance, toward increased secretion of both cy-
tokines by GM-MDM(LPS/IFNγ) relative to M-MDM(LPS/IFNγ). Contrary to previ-
ous studies [29,32], which found CCL5 to be secreted at significantly higher levels by
GM-MDM(LPS/IFNγ) relative to M-MDM(LPS/IFNγ), results from the current study
demonstrated the opposite. Hence, the above-mentioned variations in the differential secre-
tion of cytokines and chemokines between M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ)
could be related to differences in the activation method employed by different studies, more
specifically the period of exposure to LPS and IFNγ and the concentration of each activating
stimulus. The profile and level of cytokines/chemokines secreted by Mϕs have been widely
adopted as signature markers to discriminate between the two activated M1- and M2-Mϕ
phenotypes [33]. Classically activated human M1-Mϕs are typically characterized by their
IL-10low, IL-12/23p40high and/or IL-12p70high, and IL-23p19/p40high phenotype [1,34]. In
contrast, alternatively activated M2-Mϕs have an IL-10high, IL-12/23p40low and/or IL-
12p70low, and IL-23p19/p40low phenotype [35]. Several reports utilizing CSF-differentiated
human MDMs as in vitro models to study Mϕ have indicated that M-CSF and GM-CSF
are crucial determinants for shaping the functional profiles of activated Mϕs [29,36]. In
support of this notion, this study has shown that M-MDM(LPS/IFNγ) display a cytokine
secretion profile (IL-10high, IL-12/23p40low, IL-12p70low, and IL23p19/p40neg) character-
istic of the M2-Mϕ phenotype, while GM-MDM(LPS/IFNγ) display a cytokine secretion
profile (IL-10low, IL-12/23p40high, IL-12p70high, and IL23p19/p40high) characteristic of
the M1-Mϕ phenotype. These striking differences were also noted at the transcript level
whereby RNA-Seq analysis performed in this study revealed higher expression of IL10
and lower expression of IL12B (encodes for IL-12/23p40) and IL23A (encodes for IL-23p19)
in M-MDM(LPS/IFNγ) as compared to GM-MDM(LPS/IFNγ). This is in agreement
with previous studies where similar patterns of differential mRNA expression between
M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ) were reported for IL10, IL23A [36], and
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IL12B [31]. Therefore, despite being activated with the M1-activating stimuli, LPS and
IFNγ, M-MDMs remain trapped in an M2-Mϕ response mode imposed by M-CSF during
the stage of monocyte-to-Mϕ differentiation, and such a mode seems to be quite indepen-
dent of the nature of the subsequent activating stimuli. A key finding in the current study
was the demonstration that Mob-MDM(LPS/IFNγ) exhibit a distinct cytokine/chemokine
secretion profile from that of M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ). The unique
cytokine secretion profile of Mob-MDM(LPS/IFNγ) (IL-10low, IL-12/23p40low, IL-12p70neg,
and IL23p19/p40low) did not correlate either with that of M1-Mϕs (IL-12high) or with any
of those of the M2-Mϕ subtypes, M2a, M2b, M2c, or M2d, whereby high IL-10 produc-
tion is a common feature among the four of them [37]. Moreover, the distinctiveness of
Mob-MDM(LPS/IFNγ) phenotype was further reinforced by their pattern of low CXCL9
production as compared to both M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ). A pre-
vious study demonstrated that cell wall extracts from HK M. obuense and M. vaccae can
induce the production of IL-12 and TNF-α by human THP-1-derived macrophages. In this
study, IL-12 levels induced by cell wall extract of either of the two HK mycobacteria were
comparable to those induced by BCG, while TNF-α levels induced by HK M. vaccae cell
wall extract were significantly higher than those induced by BCG [38].
In the current study, RNA-Seq analysis was carried out to compare and contrast the
transcriptome profiles of the three LPS/IFNγ-activated MDM types. RNA-Seq analy-
sis identified 1546 transcripts that were significantly differentially expressed among M-
MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ). A total of 417 tran-
scripts were found to be selectively modulated in Mob-MDM(LPS/IFNγ), but not altered
between M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ) (Supplementary Materials Table
S2). Mob-MDM(LPS/IFNγ) selective transcripts encompassed a specific group of upregu-
lated proinflammatory chemokines, namely CXCL1, CXCL2, CXCL3, and CXCL5. These
four chemokines are known to share a common chemokine binding receptor, chemokine
(C-X-C) motif receptor 2 (CXCR2), and they serve as potent chemoattractants for neu-
trophils [33,39]. On the other hand, a different family of proinflammatory chemokine
transcripts (CXCL9, CXCL10, and CXL11) was found to be uniquely downregulated in
Mob-MDM(LPS/IFNγ). This family of IFN-inducible chemokines exhibits effective T
lymphocyte chemoattractant activities and is capable of binding to the cognate chemokine
receptor, CXCR3 [40,41]. Moreover, other signature proinflammatory cytokines (e.g., IFNG,
IL1B, and IL36G) were significantly upregulated in Mob-MDM(LPS/IFNγ) versus both
M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ). Several studies have highlighted the con-
tribution of IL-36γ (encoded by IL-36G) in polarizing immune cells toward type-1 immune
responses, which are pertinent to antitumor immunity [42,43]. It has been previously indi-
cated that human IL-36γ expression is inversely associated with lung and melanoma cancer
progression [44]. Transcriptomic data analysis of various immune cell populations purified
from human colorectal cancer (CRC) microenvironment has shown that IL36G is expressed
at significantly higher levels in M1-Mϕs compared to all other immune cells, including
M2-Mϕs [45,46]. Further exploration of the tumor microenvironment has uncovered a
correlation between the pattern of Mϕ IL-36γ expression and two positive prognostic
markers for CRC which comprise CD4+ central memory T-cell infiltration and augmented
density of B cells in tertiary lymphoid structures [46]. IL-36γ has been also reported to
confer protection against severe influenza infection through enhancing the survival of
mouse lung alveolar Mϕs and restraining the replication of the virus [47]. Alveolar Mϕs
isolated from uninfected IL-36γ knockout mice exhibited an M2-like Mϕ phenotype and
demonstrated an increased and rapid rate of apoptosis post influenza infection [47]. Taking
into account that HK M. obuense is currently being assessed in an ongoing clinical trial
(NCT04442048) for its capacity to decrease the occurrence and severity of coronavirus
disease 2019 (COVID-19)-related symptoms in cancer patients, it is noteworthy to further
investigate whether there is a correlation of serum IL-36γ levels with the clinical outcomes
in those patients. Results of our study identified a group of solute carriers that were se-
lectively modulated in Mob-MDM(LPS/IFNγ), whereby SLC27A2, SLC7A11, and SLC51B
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displayed an increased expression, while SLC8A1, SLC2A8, SLC2A5, and SLC6A9 showed
a decreased expression. Key physiological functions for the solute carrier family include:
transport of ions, uptake of nutrients, and elimination of cellular waste [48]. However, a
limited number of studies have addressed the functions of the above-modulated solute
carriers in human Mϕs. For instance, heat-inactivated M. tuberculosis lysate was found to
induce SLC7A11 expression in U937-derived human Mϕs [49], while SLC8A1 mediated the
release of the proinflammatory cytokine, TNFα, by human lung Mϕs [50]. SIGLEC10 was
among the top 10 transcripts of its category (others) that were uniquely and significantly
downregulated in Mob-MDM(LPS/IFNγ). The interaction between sialic acid-binding
Ig-like lectin 10 (Siglec-10) on the surface of Mϕs with CD24, commonly overexpressed on
numerous human cancers, has been previously described to be involved in the suppression
of Mϕ-mediated immune responses to cancer [51]. Targeting the CD24-Siglec-10 signal-
ing axis stands as a promising approach for cancer immunotherapy whereby blocking
Siglec-10 on human MDMs resulted in a significant increase in the phagocytic capacity of
tumor cells [52]. In this context, it would be of interest to evaluate the cytotoxic activity of
Mob-MDM(LPS/IFNγ) in vitro against CD24-expressing human cancer cell lines as well
as in vivo in humanized mouse cancer models.
RNA-Seq profiling coupled with pathways network analysis predicted nuclear factor-
κB (NF-κB) and triggering receptor expressed on myeloid cells 1 (TREM1) signaling path-
ways to be significantly activated in Mob-MDM(LPS/IFNγ) relative to both M-MDM(LPS/
IFNγ) and GM-MDM(LPS/IFNγ). The transcription factor, NF-κB, is a master regulator of
inflammatory gene expression in Mϕs [53], and it also plays a crucial role in maintaining
Mϕ viability [54]. It would be reasonable to expect that activation of the NF-κB signal-
ing pathway in Mϕs would induce the release of proinflammatory mediators (e.g., IL-6,
inducible nitric oxide synthase (iNOs), and TNF-α) [55], hence promoting the M1-Mϕ
phenotype as previously indicated [56,57]. Of note, TREM1 has been previously reported
to be an inducer of the M1-Mϕ phenotype [58] and to extend the survival of inflammatory
Mϕs [59]. TREM1 activation was shown to initiate a cascade of downstream signaling
events that would lead to the secretion of various M1 proinflammatory cytokines [58].
Upstream regulator analysis identified colony-stimulating factor 2 (CSF2; also known as
GM-CSF) as the top activated upstream regulator in Mob-(LPS/IFNγ) compared with both
M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ). GM-CSF has been previously reported to
play a pivotal role in controlling M. tuberculosis infection in human MDMs in vitro, whereby
the degree of infection control was positively correlated with GM-CSF secreted levels and
with activated GM-CSF signaling pathways in infected Mϕs [60,61]. Further studies are
clearly warranted to evaluate the antimycobacterial properties of Mob-MDM(LPS/IFNγ).
Taken together, the cytokine/chemokine release pattern of Mob-MDM(LPS/IFNγ), com-
bined with their transcriptome profile, strongly point out to a unique Mϕ phenotype,
which is quite distinct from that of M-MDM(LPS/IFNγ) and GM-MDM(LPS/IFNγ).
Previous work by our group indicated that nonactivated Mob-MDMs possess a potent
in vitro antitumor activity whereby they displayed a higher cytostatic effect against the
human pancreatic cancer cell line, BxPC3, when compared to nonactivated M-MDMs, but
their effect was comparable to that of nonactivated GM-MDMs [18]. In fact, HK M. obuense
was shown to exhibit marked immunotherapeutic effects when given in combination with
chemotherapy, in patients with metastatic pancreatic cancer [13], or in combination with
checkpoint inhibitors in patients with advanced melanoma [14]. In view of the aforemen-
tioned findings, it is reasonable to suggest that the antitumor activity of nonactivated or
LPS/IFNγ-activated Mob-MDMs is independent of their ability to release IL-12 and might
be attributed to a unique set of Mob-MDM-related genes (e.g., CSF2 and IL36G). Thus, the
potential association of these candidate genes with HK M. obuense-mediated antitumor
activity needs to be pursued in future studies. More recently, there has been a strong
but renewed interest in novel Mϕ-based approaches in cancer immunotherapy whereby
the use of chimeric antigen receptors Mϕs (CAR-Ms), currently under development, has
proven to be a promising immunotherapeutic tool against cancer [62,63]. In this manner,
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results from this study might pave the way for a potential application of HK M. obuense
in novel cell-based immunotherapeutic modalities such as the adoptive cell transfer of
autologous Mob-MDM(LPS/IFNγ) to patients with solid tumors.
4. Materials and Methods
4.1. Blood Collection
Human whole-blood samples (150–200 mL) were obtained from anonymous pheno-
typically healthy adult donors through the blood bank at Nini Hospital. Whole blood was
collected in plastic bags containing citrate-phosphate-dextrose-adenine and stored at room
temperature for 1 h prior to being processed.
4.2. Monocyte Isolation and Generation of MDMs
Whole blood was diluted with an equal volume of complete Roswell Park Memorial In-
stitute (RPMI; Merck, Darmstadt, Germany) 1640 medium (containing 100 U/mL penicillin,
100 µg/mL streptomycin penicillin, and 2 mM L-glutamine; Merck, Darmstadt, Germany).
Diluted blood was layered over Ficoll–Paque Plus (GE Healthcare, Buckingham, UK) and
centrifuged at 400× g for 40 min at 20 ◦C. Peripheral blood mononuclear cells (PBMCs)
were removed from the interface and washed twice with Dulbecco’s phosphate-buffered
saline (DPBS; Merck, Darmstadt, Germany) by centrifugation at 200× g for 15 min at 20 ◦C
to get rid of platelets. PBMCs were assessed for viability using the trypan blue exclusion
method and were always >95% viable. Later, PBMCs were seeded into 75 cm2 tissue
culture flasks at a density of 1.5 × 106 cells/mL of complete RPMI medium and incubated
overnight at 37 ◦C in a 5% CO2 humidified incubator. Cells were then washed thoroughly
with DBPS, and adherent monocytes were permitted to differentiate for 5 days into Mϕs in
complete RPMI 1640 medium supplemented with 7.5% heat-inactivated pooled human AB
serum (ZenBio, Durham, NC, USA) and with optimal concentrations [7,18,32] of M-CSF
(100 ng/mL), GM-CSF (100 ng/mL) (R&D Systems, Abingdon, UK), or 30 µg/mL HK M.
obuense (NCTC13365, Immodulon Therapeutics, UK) to generate M-MDMs, GM-MDMs,
and Mob-MDMs, respectively. MDM purity, as assessed by flow cytometry, was ~80–85%
after 5 days of differentiation.
4.3. Activation of MDMs
Following the 5-day monocyte-to-Mϕ differentiation period, M-MDMs, GM-MDMs,
and Mob-MDMs were washed thoroughly with cold DPBS and detached by gentle scraping
in cold complete RPMI 1640 medium. The viability of MDMs was ~75–80%, as evaluated
by the trypan blue dye exclusion method. Detached MDMs were seeded in a 24-well
culture plate at a density of 3 × 105 cells/well, cultured in complete RPMI 1640 medium
supplemented with 10% heat-inactivated pooled human AB serum, and were activated
with LPS from Escherichia coli O111:B4 (100 ng/mL; Merck, Darmstadt, Germany) and IFNγ
(20 ng/mL; R&D Systems, Abingdon, UK) for 24 h at 37 ◦C in a 5% CO2-humidified incuba-
tor [31,32]. LPS/IFNγ-activated M-MDMs, GM-MDMs, and Mob-MDMs were referred to
as M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-MDM(LPS/IFNγ), respectively.
4.4. Measurement of Cytokine and Chemokine Levels in MDM Culture Supernatants
Supernatants of different LPS/IFNγ-activated MDM cultures were collected by cen-
trifugation at 1000× g for 15 min at 4 ◦C, aliquoted, and stored at −80 ◦C for later cy-
tokine/chemokine analysis. Levels of different cytokines (IL-6, IL-10, IL-12/23p40, IL-
12p70, IL-23p19/p40, M-CSF, TGF-β1, and TNF-α) and chemokines (CCL2, CCL5, CCL22,
CXCL8, and CXCL9) were measured in MDM culture supernatants using sandwich enzyme-
linked immunosorbent assay (ELISA) following the protocol provided by the manufacturer
(R&D Systems, Abingdon, UK). Samples were tested in duplicate, and optical densities
of samples were recorded using a Multiskan Ascent microplate reader (Thermo Fisher
Scientific, Waltham, MA, USA).
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4.5. RNA Extraction from MDM
Total RNA was extracted from LPS/IFNγ-activated MDMs with the RNeasy Plus kit
(Qiagen, Courtaboeuf, France) following the manufacturer’s recommendations. The RNA
yield of samples was quantified using the NanoDrop 2000 spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA). RNA Quality was evaluated by calculating RNA
integrity numbers (RINs) through the use of the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA) according to the manufacturer’s guidelines. RNA samples
had a mean RIN of 8.9 (range = 8.7–9.2).
4.6. Library Preparation and RNA-Seq
A total of 800 ng of RNA was subjected to ribosomal RNA depletion using the Low
Input RiboMinus Eukaryote System v2 (Thermo Fisher Scientific, Waltham, MA, USA)
following the manufacturer’s protocol. Samples were then concentrated by vacuum cen-
trifugation, followed by the construction of whole-transcriptome libraries using the Ion
Total RNA-Seq Kit v2 (Thermo Fisher Scientific, Waltham, MA, USA) according to the
manufacturer’s instructions. Assessment of the size distribution of samples was carried
out by using the Agilent 2100 Bioanalyzer coupled with the 6000 RNA Pico kit. Library
concentrations were determined using the Agilent DNA 1000 assay on the 2100 Bioanalyzer
according to the manufacturer’s procedure. Barcoded whole-transcriptome libraries were
then diluted to 66 pM and pooled equally (13 µL each for a total of 26 µL) for sequencing
with two samples per template preparation. All template reactions were carried out on the
Ion Chef Instrument with the Ion PI Hi-Q Chef 200 kit (Thermo Fisher Scientific, Waltham,
MA, USA) based on the manufacturer’s protocol. Finally, barcoded samples were loaded
onto Ion PI Chips v3 (Thermo Fisher Scientific, Waltham, MA, USA), and sequencing was
performed with an Ion Proton sequencer (Thermo Fisher Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions.
4.7. RNA-Seq Data Analysis
An average of 36 million reads/sample were sequenced and attained 90% uniformity
of coverage. Alignment of reads was performed using Partek flow and a two-step alignment
process. Unaligned reads were initially aligned to hg19 (human reference genome) using the
STAR algorithm [64]. After the initial alignment, all unaligned reads were then realigned
with Bowtie2 version 2.1.0 [65], whereby reads from both alignment steps were then
pooled. Transcripts were then quantified using a modified version of the expectation-
maximization (E/M) algorithm, as previously defined [66]. A pseudocount was added
to all values with reads per kilobase per million (RPKM) < 1.0 followed by log (base
2) transformation and quantile normalization. The fixed-effects model with ANOVA
was employed to identify transcripts significantly differentially expressed (p < 0.05 and
2-fold change thresholds) among M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-
MDM(LPS/IFNγ) (n = 1546 transcripts, Supplementary Materials Table S1). Analysis was
carried out in the R language environment [67]. Select transcripts were also evaluated
in pairwise comparisons (e.g., M-MDM(LPS/IFNγ) compared to GM-MDM(LPS/IFNγ))
using t-tests with random variance models. Hierarchical clustering analysis was applied
to distinguish, among the differentially expressed genes, those with different patterns of
expression among the three LPS/IFNγ-activated MDM types [68,69]. Functional pathways
analysis, including gene-set enrichment and gene–gene network analysis, of differentially
expressed transcripts was conducted using Ingenuity Pathways Analysis as previously
described [70]. Raw data for M-MDM(LPS/IFNγ), GM-MDM(LPS/IFNγ), and Mob-
MDM(LPS/IFNγ) will be deposited into the Gene Expression Omnibus (GEO) under the
dataset series GSE102492.
4.8. Statistical Analysis
Statistical analysis was carried out using GraphPad Prism software (version 6; Graph-
Pad Inc., San Diego, CA, USAe). Cytokine/chemokine data are presented as mean
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values ± standard error of the mean (SEM). One-way ANOVA, followed by Tukey’s mul-
tiple comparison post-hoc test, was used to analyze cytokine/chemokine data. Values
of p < 0.05 denoted the existence of a statistically significant difference between com-
pared groups.
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